03:00 Tue 16 Apr 2019
SkinBioTherapeutics - Director/PDMR Shareholding
Director Dealing
The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 and has been arranged for release by
For more information please contact:
Dr
|
Tel: +44 (0) 161 468 2760 |
|
Tel: +44 (0) 20 7213 0880 |
Turner Pope Investments (Joint Broker)
SP Angel Corporate Finance (Joint Broker)
|
Tel: +44 (0) 20 3621 4120
Tel: +44 (0) 20 3470 0470 |
|
Tel: +44 (0) 20 7457 2020 |
About
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Dr.
SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas.
SkinBioTherapeutics received seed funding from the Tech Transfer office of the
The Company joined AIM in
The Company is based in
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 |
|||||||
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||||||
a. |
|
Dr |
|||||
2 |
Reason for notification |
Acquisition of shares |
|||||
a. |
Position/Status |
Non-Executive Director |
|||||
b. |
Initial notification/ Amendment |
Initial notification |
|||||
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||
a. |
|
|
|||||
b. |
LEI |
213800YMQOCB23FX6I06
|
|||||
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
a. |
Description of the financial instrument, type of instrument |
Ordinary shares of 1p each
ISIN: GB00BF33H870
|
|||||
b. |
Nature of the transaction |
Share purchase |
|||||
c. |
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) per share |
Volume(s) |
|
||||
17.82p |
56,112 |
|
|||||
|
|||||||
d. |
Aggregated information
- Aggregated Volume
- Price |
56,112
17.82p
|
|||||
e. |
Date of the transaction |
15th |
|||||
f. |
Place of the transaction |
|
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE